Home » Amgen, UCB’s Osteoporosis Candidate Shines in Phase 3 Trial
Amgen, UCB’s Osteoporosis Candidate Shines in Phase 3 Trial
Amgen and UCB’s romosozumab met its primary endpoints in a Phase 3 study by reducing new vertebral fractures in postmenopausal women with osteoporosis through months 12 and 24.
The candidate also met a secondary endpoint of reducing the incidence of clinical fractures through 12 months, but missed its secondary endpoint of reducing the incidence of non-vertebral fractures through months 12 and 24.
Upcoming Events
-
14May
-
23May
-
30May
-
20Jun
-
21Oct